Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1992 Jan;47(1):30-3.
doi: 10.1136/thx.47.1.30.

Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic

Affiliations
Clinical Trial

Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic

E Y Derom et al. Thorax. 1992 Jan.

Abstract

Background: Most of the currently available inhaled beta 2 agonists are short acting bronchodilators. The aim of this study was to compare the rate of onset and duration of the bronchodilating activity of formoterol and salbutamol.

Methods: Fourteen patients with reversible airways obstruction received placebo, 200 micrograms salbutamol, and 12, 24, and 48 micrograms formoterol from a metered dose inhaler, according to a double blind, randomised crossover design. Forced expiratory volume in one second (FEV1) and specific airways conductance (sGaw) were measured over 12 hours.

Results: Salbutamol and all doses of formoterol caused a significant and substantial increase in sGaw one minute after inhalation. The mean maximum increase in FEV1 was 58% (8%) after 200 micrograms salbutamol compared with 63% (11%), 62% (10%), and 74% (10%) after 12, 24, and 48 micrograms formoterol, respectively. The mean maximum increase in FEV1 occurred 57 (12) minutes after administration of salbutamol compared with 137 (16), 141 (21), and 161 (33) minutes after 12, 24, and 48 micrograms formoterol respectively. The bronchodilating effect of salbutamol did not differ from placebo after six hours. In contrast, the mean increase in FEV1 12 hours after 12 micrograms formoterol (26% (8%) of baseline) significantly exceeded the change after placebo. Tremor was recorded in four patients after 48 micrograms formoterol.

Conclusion: Formoterol is a potent, fast acting bronchodilator with a long duration of action.

PubMed Disclaimer

References

    1. Am Rev Respir Dis. 1975 Apr;111(4):433-9 - PubMed
    1. J Allergy Clin Immunol. 1987 Jan;79(1):78-85 - PubMed
    1. Allergy. 1989 May;44(4):264-71 - PubMed
    1. Chest. 1990 Mar;97(3):590-4 - PubMed

Publication types